211 related articles for article (PubMed ID: 19394511)
1. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
Inoue T; Segawa T; Kamba T; Yoshimura K; Nakamura E; Nishiyama H; Ito N; Kamoto T; Habuchi T; Ogawa O
Urology; 2009 May; 73(5):1104-9. PubMed ID: 19394511
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
3. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
[TBL] [Abstract][Full Text] [Related]
4. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors.
Hernes EH; Linja M; Fosså SD; Visakorpi T; Berner A; Winderen M; Koivisto PA
BJU Int; 2000 Aug; 86(3):240-7. PubMed ID: 10930923
[TBL] [Abstract][Full Text] [Related]
5. Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy.
Wong KW; Ma WK; Wong CW; Wong MH; Tsang CF; Tsu HL; Ho KL; Yiu MK
Hong Kong Med J; 2016 Apr; 22(2):106-15. PubMed ID: 26635306
[TBL] [Abstract][Full Text] [Related]
6. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.
Oudard S; Banu E; Scotte F; Banu A; Medioni J; Beuzeboc P; Joly F; Ferrero JM; Goldwasser F; Andrieu JM
Ann Oncol; 2007 Nov; 18(11):1828-33. PubMed ID: 17846024
[TBL] [Abstract][Full Text] [Related]
9. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
[TBL] [Abstract][Full Text] [Related]
10. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone.
Morioka M; Kobayashi T; Furukawa Y; Jo Y; Shinkai M; Matsuki T; Yamamoto T; Tanaka H
Urol Int; 2002; 68(1):10-5. PubMed ID: 11803262
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
[TBL] [Abstract][Full Text] [Related]
13. Complications and survival after surgical treatment of 214 metastatic lesions of the humerus.
Wedin R; Hansen BH; Laitinen M; Trovik C; Zaikova O; Bergh P; Kalén A; Schwarz-Lausten G; Vult von Steyern F; Walloe A; Keller J; Weiss RJ
J Shoulder Elbow Surg; 2012 Aug; 21(8):1049-55. PubMed ID: 21982491
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan.
Sasaki T; Nakamura K; Ogawa K; Onishi H; Okamoto A; Koizumi M; Shioyama Y; Mitsumori M; Teshima T;
BJU Int; 2009 Nov; 104(10):1462-6. PubMed ID: 19522869
[TBL] [Abstract][Full Text] [Related]
15. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Oudard S; Banu E; Medioni J; Scotte F; Banu A; Levy E; Wasserman J; Kacso G; Andrieu JM
BJU Int; 2009 Jun; 103(12):1641-6. PubMed ID: 19210673
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
17. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
18. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
19. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
20. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
